Harrow, an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the launch of atropine.com, an easy-to-access ordering and marketing portal that is designed specifically for prescribers interested in compounded atropine formulations.
All atropine.com prescriptions will be dispensed through Harrow’s wholly owned subsidiary, ImprimisRx.
Harrow’s compounded atropine formulations undergo a strict series of validated analytical tests to ensure consistency, potency, and stability; are stable at a biologically comfortable pH; and are now available in three concentrations (0.01%, 0.025%, and 0.05%) for as low as $39 per bottle, according to Mark L. Baum, Harrow’s chairman and CEO.
“While our current suite of compounded atropine formulations is available for individual patients through the ImprimisRx 503, a national mail-order pharmacy, we intend to make a patent-pending suite of compounded atropine formulations that does not contain either preservatives or boric acid,” Baum stated. “This suite of products will be available soon to healthcare facilities through our 503B outsourcing facility—with or without a patient-specific prescription.”
Eyecare professionals can prescribe atropine for individual patients online at atropine.com or by calling ImprimisRx Customer Care at (844) 446-6979.
Healthcare providers may sign up for updates on the availability of atropine formulations through the ImprimisRx FDA-registered and FDA-inspected 503B outsourcing facility.